View in EDS

MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC.

Saved in:
Bibliographic Details
Title: MO1-2 Safety profile of LIGHT-NING 3rd interim analysis: 1L nivolumab + ipilimumab +/− chemotherapy for metastatic NSCLC.
Authors: Azuma, K.1 (AUTHOR), Imai, H.2 (AUTHOR), Yamaguchi, T.3 (AUTHOR), Kijima, T.4 (AUTHOR), Kishi, K.5 (AUTHOR), Fujita, K.6 (AUTHOR), Saito, H.7 (AUTHOR), Shiraishi, Y.8 (AUTHOR), Tanizaki, J.9 (AUTHOR), Takashima, Y.10 (AUTHOR), Tambo, Y.11 (AUTHOR), Watanabe, S.12 (AUTHOR), Hataji, O.13 (AUTHOR), Toi, Y.14 (AUTHOR), Fukuhara, T.15 (AUTHOR), Ohsugi, T.16 (AUTHOR), Kuroda, H.17 (AUTHOR), Ohe, Y.18 (AUTHOR), Horinouchi, H.18 (AUTHOR)
Source: Annals of Oncology. Oct2024:Supplement 3, Vol. 35, pS1328-S1328. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1016/j.annonc.2024.07.515